McKesson Corporation $MCK Shares Bought by Quantbot Technologies LP

Quantbot Technologies LP grew its position in shares of McKesson Corporation (NYSE:MCK) by 536.8% during the third quarter, HoldingsChannel reports. The firm owned 12,137 shares of the company’s stock after buying an additional 10,231 shares during the period. Quantbot Technologies LP’s holdings in McKesson were worth $9,376,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank purchased a new stake in McKesson during the 2nd quarter worth $1,346,661,000. Alliancebernstein L.P. grew its stake in shares of McKesson by 150.4% during the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after acquiring an additional 1,362,386 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of McKesson by 56.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after acquiring an additional 446,060 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of McKesson by 45.6% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after acquiring an additional 261,296 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in McKesson by 68.0% in the second quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock valued at $466,441,000 after purchasing an additional 257,670 shares during the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. TD Cowen upped their target price on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. boosted their price objective on McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Wall Street Zen downgraded McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Evercore reiterated an “outperform” rating and issued a $1,000.00 target price on shares of McKesson in a research note on Thursday, November 6th. Finally, Wells Fargo & Company upped their price target on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $943.50.

McKesson Stock Up 1.0%

Shares of NYSE MCK opened at $984.61 on Friday. The stock has a market cap of $120.60 billion, a P/E ratio of 28.32, a P/E/G ratio of 1.57 and a beta of 0.40. The firm’s 50-day simple moving average is $868.77 and its 200 day simple moving average is $805.52. McKesson Corporation has a fifty-two week low of $621.88 and a fifty-two week high of $987.37.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the company earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, sell-side analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s payout ratio is presently 9.43%.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,143 shares of company stock valued at $1,046,070 in the last ninety days. 0.08% of the stock is owned by insiders.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.